FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 495 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Rare Melanoma Very Likely to Respond to Treatment with Pembrolizumab May 5, 2023 EMA Recommends Extension of Indications for Olaparib September 24, 2020 Cabozantinib Plus Nivolumab and Ipilimumab Results in Longer PFS in Previously... May 19, 2023 EMA Recommends Granting a Marketing Authorisation for Lisocabtagene Maraleucel February 4, 2022 Load more HOT NEWS The R50 Research Specialist Award: Ensuring a Stable Cancer Research Workforce Tips On Staying Cool During a Heat Wave EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan Veteran Dresses As Captain America & Brings Joy To Children In...
